GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CKD-501, D745, D150

Company
Chong Kun Dang Pharmaceutical
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT04334213

    A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150

    Not yet reported Chong Kun Dang Pharmaceutical 48 participants Est. completion 2020-08-05 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04810676

    A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

    Not yet reported Chong Kun Dang Pharmaceutical 27 participants Est. completion 2021-05-26 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05897216

    Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

    Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2023-08-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07304687

    Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers

    Not yet reported Chong Kun Dang Pharmaceutical 31 participants Est. completion 2025-11-22 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07304726

    Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers

    Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2025-11-23 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.